|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.02 EUR | +1.25% |
|
-0.22% | +10.48% |
| 05:42pm | GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial | AN |
| 05:09pm | GSK, Hansoh's targeted cancer drug hits main survival goal in China trial | RE |
| Market Cap | 7.81TCr 10TCr 9.17TCr 8.45TCr 15TCr 9,99300Cr 15TCr 1,01000Cr 40TCr 4,92300Cr 39TCr 38TCr 16,92500Cr | P/E 2026 * |
12.4x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 9.34TCr 13TCr 11TCr 10TCr 18TCr 11,95000Cr 18TCr 1,20800Cr 47TCr 5,88700Cr 47TCr 46TCr 20,23800Cr | EV / Sales 2026 * |
2.76x | EV / Sales 2027 * | 2.54x |
| Free-Float |
92.29% | Yield 2026 * |
3.56% | Yield 2027 * | 3.74% |
Last Transcript: GSK plc
| 1 day | +1.28% | ||
| 1 week | -0.22% | ||
| Current month | +0.30% | ||
| 1 month | +4.18% | ||
| 3 months | -6.19% | ||
| 6 months | +8.11% | ||
| Current year | +10.48% |
| 1 week | 22.69 |  | 23.7 |
| 1 month | 22 | | 23.7 |
| Current year | 20.27 | | 26.02 |
| 1 year | 15.35 | | 26.02 |
| 3 years | 14.68 | | 26.02 |
| 5 years | 14.62 | | 27.13 |
| 10 years | 14.62 | | 27.52 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.25% | -0.22% | - | - | 10TCr | |
| -2.46% | -1.36% | +49.72% | +161.22% | 1,08500Cr | |
| -1.04% | -1.10% | +62.65% | +60.80% | 62TCr | |
| -1.40% | -3.33% | +26.30% | +83.12% | 44TCr | |
| +0.33% | -1.17% | +27.98% | +26.90% | 33TCr | |
| -3.89% | -11.22% | +20.78% | +26.07% | 28TCr | |
| -0.02% | -2.85% | +25.27% | +44.88% | 28TCr | |
| +0.66% | -1.42% | -29.26% | -39.30% | 22TCr | |
| -0.59% | -1.29% | +20.42% | +60.95% | 20TCr | |
| -3.79% | +0.23% | +13.42% | +71.63% | 17TCr | |
| Average | -1.16% | -1.86% | +24.14% | +55.14% | 40.24TCr | |
| Weighted average by Cap. | -1.51% | -1.06% | +34.99% | +81.12% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.39TCr 4.55TCr 3.98TCr 3.67TCr 6.43TCr 4,33600Cr 6.54TCr 44TCr 17TCr 2,13600Cr 17TCr 17TCr 7,34400Cr | 3.56TCr 4.78TCr 4.18TCr 3.86TCr 6.76TCr 4,55700Cr 6.87TCr 46TCr 18TCr 2,24500Cr 18TCr 18TCr 7,71800Cr |
| Net income | 652.29Cr 875.36Cr 765.68Cr 706.24Cr 1.24TCr 83TCr 1.26TCr 8.44TCr 3.31TCr 41TCr 3.29TCr 3.22TCr 1,41400Cr | 704.44Cr 945.36Cr 826.91Cr 762.72Cr 1.34TCr 90TCr 1.36TCr 9.11TCr 3.58TCr 44TCr 3.55TCr 3.47TCr 1,52700Cr |
| Net Debt | 1.53TCr 2.05TCr 1.79TCr 1.66TCr 2.9TCr 1,95700Cr 2.95TCr 20TCr 7.77TCr 96TCr 7.7TCr 7.54TCr 3,31400Cr | 1.22TCr 1.64TCr 1.43TCr 1.32TCr 2.32TCr 1,56500Cr 2.36TCr 16TCr 6.21TCr 77TCr 6.16TCr 6.03TCr 2,65000Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/26/10 | €23.20 | +2.02% | 250 |
| 09/26/09 | €22.74 | -0.61% | 525 |
| 08/26/08 | €22.88 | -1.34% | 220 |
| 07/26/07 | €23.19 | -0.13% | 237 |
| 06/26/06 | €23.22 | -0.13% | 2,372 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GS71 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
